Aristoff, P.A., Johnson, P.D., and Harrison, A.W. Synthesis of 9-substituted carbacyclin analogues. J Org Chem 48 5341-5348 (1983).

Nakagawa, O., Tanaka, I., Usui, T., et al. Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. Circulation 90 1643-1647 (1994).

Namba, T., Oida, H., Sugimoto, Y., et al. cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla. J Biol Chem 269 9986-9992 (1994).

Smyth, E.M., Nestor, P.V., and Fitzgerald, G.A. Agonist-dependent phosphorylation of an epitope-tagged human prostacyclin receptor. J Biol Chem 271(52) 33698-33704 (1996).

McLaughlin, V.V., Genthner, D.E., Panella, M.M., et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338 273-277 (1998).

Southall, M.D., and Vasko, M.R. Prostaglandin receptor subtypes, EP3C and EP₄, mediate the prostaglandin E₂-induced cAMP production and sensitization of sensory neurons. J Biol Chem 276(19) 16083-16091 (2001).

Murata, T., Ushikubi, F., Matsuoka, T., et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388 678-682 (1997).

Cui, Y., Kataoka, Y., Satoh, T., et al. Protective effect of prostaglandin I₂ analogs on ischemic delayed neuronal damage in gerbils. Biochem Biophys Res Commun 265 301-304 (1999).

Cheng, Y., Austin, S.C., Rocca, B., et al. Role of prostacyclin in the cardiovascular response to thromboxane A₂. Science 296 539-541 (2002).

1 Aristoff, P.A., Johnson, P.D., and Harrison, A.W. Synthesis of 9-substituted carbacyclin analogues. J Org Chem 48 5341-5348 (1983).

2 Southall, M.D., and Vasko, M.R. Prostaglandin receptor subtypes, EP3C and EP₄, mediate the prostaglandin E₂-induced cAMP production and sensitization of sensory neurons. J Biol Chem 276(19) 16083-16091 (2001).

3 Murata, T., Ushikubi, F., Matsuoka, T., et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388 678-682 (1997).

4 Cheng, Y., Austin, S.C., Rocca, B., et al. Role of prostacyclin in the cardiovascular response to thromboxane A₂. Science 296 539-541 (2002).

5 Cui, Y., Kataoka, Y., Satoh, T., et al. Protective effect of prostaglandin I₂ analogs on ischemic delayed neuronal damage in gerbils. Biochem Biophys Res Commun 265 301-304 (1999).

6 McLaughlin, V.V., Genthner, D.E., Panella, M.M., et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338 273-277 (1998).

7 Nakagawa, O., Tanaka, I., Usui, T., et al. Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. Circulation 90 1643-1647 (1994).

8 Namba, T., Oida, H., Sugimoto, Y., et al. cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla. J Biol Chem 269 9986-9992 (1994).

9 Smyth, E.M., Nestor, P.V., and Fitzgerald, G.A. Agonist-dependent phosphorylation of an epitope-tagged human prostacyclin receptor. J Biol Chem 271(52) 33698-33704 (1996).